Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Uni-Bio Science Group Ltd. ( (HK:0690) ) has shared an update.
Uni-Bio Science Group Limited has extended the maturity of existing loans advanced by a wholly owned subsidiary to connected parties Dongguan Taili and Guangzhou Taili from 31 December 2025 to 31 December 2027, under new extension agreements signed on 29 December 2025. The DG Loan of RMB8.5 million will continue to bear interest at 3% per annum from 1 January 2026, payable quarterly, and remains secured by a pledge over two invention patents owned by Guangzhou Taili; the transaction is classified as a connected transaction under Hong Kong Listing Rules, triggering announcement and reporting obligations but remaining exempt from circular and independent shareholders’ approval requirements due to its size, signalling limited shareholder approval risk while formalizing continued financial support to related parties.
The most recent analyst rating on (HK:0690) stock is a Hold with a HK$0.12 price target. To see the full list of analyst forecasts on Uni-Bio Science Group Ltd. stock, see the HK:0690 Stock Forecast page.
More about Uni-Bio Science Group Ltd.
Uni-Bio Science Group Limited is a Hong Kong–listed biopharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products, with operations conducted through various subsidiaries. The group’s activities include providing loans to related entities within its corporate structure as part of its treasury and capital management arrangements.
Average Trading Volume: 6,784,165
Technical Sentiment Signal: Buy
Current Market Cap: HK$691M
See more insights into 0690 stock on TipRanks’ Stock Analysis page.